The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population

  • Jong Hyun Yoon
  • Hee Jo Yang
  • Jae Heon Kim
  • Seung Whan Doo
  • Won Jae Yang
  • Jiyoung Hwang
  • Seong Sook Hong
  • Suyeon Park
  • Dae Yeon Cho

Abstract

Introduction: We sought to investigate the impact of fatty liver disease (FLD) on prostate cancer (PCa) screening by estimating the odds of having a prostate-specific antigen (PSA) value over the cutoff used  to prompt for the recommendation of prostate biopsy.

Methods: Between 2007 and 2013, 18 533 native Korean men eligible to receive a serum PSA test, liver profiles, and abdominal ultrasonography were recruited. Logistic regression was used to estimate the odds of an abnormal PSA (≥2.5 ng/mL) in these men (age 45-75 years, PSA≤10 ng/mL) in relation to FLD. The FLD status was categorized as normal, mild, moderate, and severe grade by abdominal sonography.

Results: A total of 16 563 men (89.4%) were included in the study after applying the inclusion criteria. Liver profiles were negatively correlated with the serum PSA level. After controlling for age and obesity, there was a statistically significant trend towards a lower likelihood of having a serum PSA level of ≥2.5 ng/mL with severe FLD, having a 34.7% lower likelihood (odds ratio 0.653, 95% confidence interval 0.477–0.88; p<0.01) compared to men in the normal group.

Conclusions: Severe FLD is an independent predictor of a lower likelihood of having abnormal PSA level. Further studies are needed to better define these results in clinical biopsy practice.

Published
2015-12-14
How to Cite
Yoon, J. H., Yang, H. J., Kim, J. H., Doo, S. W., Yang, W. J., Hwang, J., Hong, S. S., Park, S., & Cho, D. Y. (2015). The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population. Canadian Urological Association Journal, 9(11-12), E868-72. https://doi.org/10.5489/cuaj.2395
Section
Original Research